Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Sarepta stock fell after it agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular ...

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility]( ...

Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on ...

Implied Volatility Surging for Sarepta (SRPT) Stock Options. Zacks Equity Research . Fri, May 24, 2024, 11:57 AM 2 min read. In This Article: SRPT .

Investors in Sarepta Therapeutics, Inc. SRPT need to pay close attention to the stock based on moves in the options market lately.That is because the Oct 18, 2024 $80 Call had some of the highest ...

Investors in Sarepta Therapeutics, Inc. SRPT need to pay close attention to the stock based on moves in the options market lately. That is because.